Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

Juan W. Valle

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1999-0863; OpenAlex author ID A5077826150. Sources: ClinicalTrials.gov.

Their work

Papers
47 (first author 3, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
153
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 4 papers · 2015: 1 paper · 2016: 2 papers · 2017: 3 papers, 1 trial · 2018: 4 papers · 2019: 6 papers · 2020: 7 papers · 2021: 6 papers · 2022: 3 papers · 2023: 7 papers · 2024: none · 2025: 3 papers

Papers 47

  1. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  2. An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. Co-author DOI 10.1093/bjr/tqae217↗
  3. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  4. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  5. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02170-9↗
  6. The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. Co-author DOI 10.1038/s41416-023-02220-2↗
  7. PACT-UK (PAncreatic Cancer reporting Template-UK): a cross-specialty multi-institutional consensus panel development of a standardised radiological reporting p… Co-author DOI 10.1136/bmjonc-2023-000055↗
  8. Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. Co-author DOI 10.3390/cancers15030738↗
  9. Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy … Last author DOI 10.3390/cancers15082277↗
  10. Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre. Co-author DOI 10.3390/healthcare11202802↗
  11. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2022.02.014↗
  12. Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemothera… Co-author DOI 10.1080/0284186x.2022.2053198↗
  13. The microbiome as a potential diagnostic biomarker for pancreatic ductal adenocarcinoma (PDAC). First author DOI 10.21037/hbsn-22-380↗
  14. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2021.04.031↗
  15. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  16. Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Co-author DOI 10.1038/s41467-021-27607-8↗
  17. Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy … Last author DOI 10.1136/bmjopen-2020-042067↗
  18. The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer. Co-author DOI 10.3390/cancers13153779↗
  19. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  20. PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. Co-author DOI 10.1016/j.clon.2019.07.011↗
  21. The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. Last author DOI 10.1016/j.pan.2020.03.020↗
  22. Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.09.012↗
  23. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(20)30974-0↗
  24. Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-020-0846-2↗
  25. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  26. The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001486↗
  27. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  28. Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1002/jso.25440↗
  29. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Co-author DOI 10.1016/j.pan.2018.10.003↗
  30. Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Co-author DOI 10.1038/s41598-019-47489-7↗
  31. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  32. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. Last author DOI 10.4251/wjgo.v11.i2.102↗
  33. Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? Co-author DOI 10.1016/j.ejso.2018.07.047↗
  34. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  35. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  36. Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Co-author DOI 10.3390/cancers10010017↗
  37. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  38. Germline mutations in pancreatic cancer and potential new therapeutic options. First author DOI 10.18632/oncotarget.17291↗
  39. Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.3390/ijms18050909↗
  40. 18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Last author DOI 10.1016/j.critrevonc.2015.12.014↗
  41. Pancreatic cancer: Are "liquid biopsies" ready for prime-time? First author DOI 10.3748/wjg.v22.i32.7175↗
  42. A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. Co-author DOI 10.1007/s12029-015-9724-1↗
  43. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patie… Co-author DOI 10.1007/s00262-013-1502-y↗
  44. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗
  45. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  46. Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Co-author DOI 10.1593/tlo.13724↗
  47. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Co-author DOI 10.1038/bjc.2011.545↗

Trials 1

  1. Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer Principal investigator NCT04161417↗

Closest collaborators

The 25 strongest of 153 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mairead Geraldine McNamara · 21 shared papers, 2016–2023 · strength 2.71
  2. Ángela Lamarca · 17 shared papers, 2016–2023 · strength 2.09
  3. Richard A Hubner · 15 shared papers, 2016–2023 · strength 1.85
  4. Daniel H. Palmer · 13 shared papers, 2014–2025 · strength 1.03
  5. Ganesh Radhakrishna · 7 shared papers, 2014–2025 · strength 1.01
  6. Paula Ghaneh · 11 shared papers, 2014–2025 · strength 0.88
  7. Rille Pihlak · 7 shared papers, 2017–2023 · strength 0.80
  8. John P. Neoptolemos · 11 shared papers, 2014–2025 · strength 0.75
  9. Nigel Balfour Jamieson · 5 shared papers, 2020–2025 · strength 0.72
  10. Derek A O'Reilly · 8 shared papers, 2017–2023 · strength 0.70
  11. Christopher Michael Halloran · 9 shared papers, 2014–2025 · strength 0.69
  12. Alan Anthoney · 10 shared papers, 2014–2022 · strength 0.64
  13. Bengt L. G. Glimelius · 8 shared papers, 2014–2025 · strength 0.57
  14. Lindsay E. Carnie · 4 shared papers, 2020–2023 · strength 0.55
  15. David Cunningham · 7 shared papers, 2014–2025 · strength 0.55
  16. John A. G. Moir · 2 shared papers, 2023–2025 · strength 0.52
  17. Raneem Albazaz · 2 shared papers, 2023–2025 · strength 0.52
  18. Pippa G. Corrie · 6 shared papers, 2014–2023 · strength 0.50
  19. Thilo Hackert · 5 shared papers, 2017–2025 · strength 0.48
  20. Markus Wolfgang Büchler · 7 shared papers, 2014–2023 · strength 0.47
  21. Harpreet Singh Wasan · 5 shared papers, 2017–2025 · strength 0.46
  22. Yuk Ting Ma · 5 shared papers, 2017–2025 · strength 0.46
  23. Paul J. Ross · 5 shared papers, 2014–2025 · strength 0.42
  24. Nicola de Liguori Carino · 3 shared papers, 2018–2022 · strength 0.37
  25. Julia V. Mayerle · 6 shared papers, 2014–2021 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.